Drugs / SPH9788
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06839131 | Mar 2025 → Dec 2026 expected | — | Shanghai Pharmaceuticals Holding Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SPH9788 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06839131 ↗ |
| Route | Oral | “SPH9788 tablets administered orally” NCT06839131 ↗ |